Bank of Montreal, Canada: Reiterated the Acrivon Therapeutics (ACRV.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $25.00 to $25.00.

Bank of Montreal, Canada: Reiterated the Acrivon Therapeutics (ACRV.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $25.00 to $25.00.

Zhitong FinanceMay 15 21:03

BMO Capital Reiterates Outperform on Acrivon Therapeutics, Maintains $25 Price Target

BMO Capital analyst Etzer Darout reiterates Acrivon Therapeutics with a Outperform and maintains $25 price target.

Analyst UpgradesMay 15 20:55

Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), Arcutis Biotherapeutics (ARQT) and TruBridge (TBRG)

TipRanksMay 15 11:20

Acrivon Therapeutics Price Target Raised to $22.00/Share From $20.00 by HC Wainwright & Co.

Acrivon Therapeutics Price Target Raised to $22.00/Share From $20.00 by HC Wainwright & Co.

Dow JonesMay 15 01:28

Acrivon Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Acrivon Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 15 01:28

HC Wainwright & Co. : The Acrivon Therapeutics (ACRV.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $20.00 to $22.00.

HC Wainwright & Co. : The Acrivon Therapeutics (ACRV.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $20.00 to $22.00.

Zhitong FinanceMay 15 01:20